QLC1101 / Qilu Pharma - LARVOL DELTA

Safety and Efficacy of QLC1101 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS G12D Mutation (IASLC-WCLC 2026) - P1 | "Conclusions : QLC1101 was well tolerated in pts with advanced KRAS G12D mutant NSCLC, and showed preliminary antitumor activity, which support further investigation of QLC1101. Pts enrollment for other solid tumors, including pancreatic ductal adenocarcinoma, is ongoing."

Clinical • First-in-human • Metastases • Dyslipidemia • Hypertriglyceridemia • Lung Cancer • Metabolic Disorders • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • KRAS

Safety and efficacy of QLC1101 in KRAS G12D-mutant advanced solid tumors: results from a phase 1a study [WITHDRAWN] (AACR 2025) - "Abstract is embargoed at this time."

Clinical • Metastases • P1 data • Oncology • Solid Tumor • KRAS

The Food Effect on Pharmacokinetics Study of QLC1101 in Healthy Subjects (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

New P1 trial

A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation (clinicaltrials.gov) - P1/2 | N=240 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

New P1/2 trial • Solid Tumor • KRAS

A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=250 | Recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

Metastases • Monotherapy • New P1 trial • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS